Lunch and Learn Series - Mar 7th, 2017

Funding and Exit Strategies:
The Value of a Biotech Business

BioPharma Consortium

in collaboration with

JLabs Bay Area

When:      Tuesday, March 7, 2017 from 9:45 AM to 12:00 PM (PST)

Where:     JLABS @ SSF
                  329 Oyster Point Blvd - 3rd Floor
                  South San Francisco, CA

(For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)

Pricing:   $25 | General Public
               $35 | Onsite

Biotech companies... do you know your worth? The wise startup company plans their exit from the beginning. In order to properly leverage your exit value you need to understand the different valuation methods, how they are used and who is using them.

John Selig, Managing Partner and co-founder of Mavericks Capital, a healthcare investment bank, will guide you through the maze of sunk costs, sum of parts, comparables, Discounted Cash Flow (DTC) and Net Present Value (NPV) to help you increase negotiating leverage and make more informed funding decisions.

Join us for an informative and interactive session.

Topics Covered:

  • The different valuation methodologies and who is using them
  • Key approaches in funding for life science companies
  • Planning exit strategies and deal structuring from the outset
  • How do my expected deal terms relate to my forecast cash flows and how can I use this to make better decisions on licensing timing?

In cooperation with JLABS SSF.
Visit for more information. 

9:45am | Registration
10:00am | Presentation and Q&A
11:30am | Lunch and Networking
12:00 | Program close


John Selig | Managing Partner, Mavericks Capital
John advises life science companies on M&A, licensing and financial strategy. He speaks frequently on topics in valuation, deal term benchmarking, and strategy in the life sciences space, including the Valuation and Finance module at BIO's Executive Management Training course for BD professionals each year and the Valuation lecture at Stanford Medical School's Entrepreneurship Program. Prior to joining Maverick's, John co-led the Life Sciences Group at Woodside Capital Partners, a boutique investment bank. For the prior 12 years, he advised both Fortune 100 and VC - backed healthcare companies on transaction strategy and valuation at Strategic Decisions Group (SDG), a global management consulting firm, and Keelin Reeds Partners, a life sciences consulting firm. While at Keelin Reeds, John led a partnership and M&A deal term benchmarking effort and has extensive experience in applying that data to yield market-value deal terms for dozens of assets, using the results to provide ongoing support during deal negotiations. Prior to consulting, John was an attorney with Weil, Gotshal and Manges where he focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he was an Associate Editor of Law Review, and a BA, magna cum laude, from Brown University, where he was a member of Phi Beta Kappa (FINRA 24, 63, 79).

(For BPC's 30% discount, enter "BioConsortium" in the Promotional Code field)